Genomic Vision
In Brief This Week: Genomic Vision, LabCorp, TriLink, and More
Genomic Vision announced this week that it has received a second payment from Quest Diagnostics related to the companies' collaboration for the development of new biomarkers to improve the genetic detection of spinal muscular atrophy. The company declined to disclose the amount of the payment.
Genomic Vision, Quest Extend Spinal Muscular Atrophy Collaboration
The companies are accelerating the pace of an existing collaboration with the goal of detecting SMA "2+0" carrier status.
In Brief This Week: Genomic Vision, Quest Diagnostics, Clongen Laboratories, NeoGenomics
Genomic Vision said that its third quarter revenues grew 27 percent year over year with a sharp spike in in vitro diagnostic sales. The firm posted total revenues of €701,000 ($825,000) for the three months ending on Sept. 30, up from €550,000 in Q3 2016.
Genomic Vision, AmCare Genomics Ink Deal to Distribute Muscular Dystrophy Assay in China
AmCare Genomics said that it has a large network that would enable it to raise awareness about Genomic Vision's test for facioscapulohumeral muscular dystrophy.
Genomic Vision 1H 2017 Revenues Up 15 Percent
The growth was driven in part by a strong increase in revenues for the company's life sciences research products.